Oral Abstract II: Impact of Pharmacogenetics in Real-Life Settings

OAII-001 EVALUATION OF PHARMACOGENOMIC MEDICATION PRESCRIBING PATTERNS IN RURAL VERSUS URBAN SETTINGS.
A. Radwan¹, C. Roeder², D. Kao³, H. Anderson⁴, J. Martin⁵, E. Woodahl⁶, C. Aquilante⁴; ¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States, ²University of Colorado School of Medicine, Aurora, CO, United States, ³University of Colorado School of Medicine⁴University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences⁵University of Colorado Anschutz Medical Campus⁶University of Montana.

OAII-002 ALCOHOL USE DISORDER PHARMACOGENOMICS: ROLE OF FNDC4 IN HUMAN NEURONAL FUNCTION.
X. Zhu¹, D. Liu², A. John², H. Gao², B. Coombes², J. Biernacka², V. Karpyak², R. Weinshilboum²; ¹Mayo Clinic, Mayo Clinic, Rochester, MN²Mayo Clinic.

OAII-003 A LONGITUDINAL HBA1C MODEL IN PATIENTS WITH TYPE 2 DIABETES ELUCIDATES THE ROLE OF CODING VARIANT IN GLUCOSE TRANSPORTER GENE, SLC2A2, ON GLYCEMIC RESPONSE TO METFORMIN.
E. Yang¹, A. Riselli¹, F. Xu², S. Sridhar², M. Kvale¹, K. Giacomini¹, M. Hedderson², S. Yee¹, R. Savic¹; ¹University of California, San Francisco²Kaiser Permanente Northern California.

OAII-004 CARE TEAM ATTRIBUTES PREDICT LIKELIHOOD OF UTILIZING PHARMACOGENOMIC INFORMATION.
Z. Huang¹, M. Jack², R. Knoebel², K. O'Leary³, E. Nutsecu⁴, T. Chen², K. Yeo², S. Hartman², A. Choksi², G. Ruhnke², M. Perera³, M. Ratain², D. Meltzer², P. O'Donnell²; ¹University of Chicago Pritzker school of Medicine, ²The University of Chicago, ³Northwestern University, ⁴University of Illinois Chicago.